Hepatitis Drug Development Market Research Report, Analysis, Opportunities, Forecast, Revenue, Trends, Value : Ken Research

1

• Hepatitis Drug Development Market Research
  Report Ken Research

2

• Hepatitis Drug Development Market Research Report
  provides an overview of the pipeline landscape
  for hepatitis infections. It provides
  comprehensive information on the therapeutics
  under development and key players involved in
  therapeutic development for hepatitis A,
  hepatitis B, hepatitis D and hepatitis E, and
  features dormant and discontinued products.
• Hepatitis refers to inflammation of the liver and
  is most commonly caused by viral infections.
  Hepatitis A and E are typically caused by
  ingestion of contaminated food or water. Symptoms
  of hepatitis A infection include fatigue, nausea
  and vomiting, loss of appetite, dark urine,
  muscle pain and yellowing of the skin and eyes.
• Risk factors include a weakened immune system and
  use of injected or non-injected illicit drugs.
  Symptoms of hepatitis E include yellowing of the
  skin, dark urine, fever, fatigue, joint pain,
  nausea, a loss of appetite and pain in the
  abdomen.

3

• Hepatitis B and hepatitis D infection typically
  occur as a result of contact with infected body
  fluids. Transmission of hepatitis B can occur via
  sexual contact, injection drug use or
  transfusions of contaminated blood and blood
  products. Hepatitis B virus can cause an acute
  illness with symptoms that last several weeks,
  including yellowing of the skin and eyes, dark
  urine, extreme fatigue, nausea, vomiting and
  abdominal pain.
• Hepatitis D infection only occurs in persons
  previously infected with hepatitis B, as the
  hepatitis D virus can only replicate in the
  presence of hepatitis B. The co-infection of
  hepatitis B and hepatitis D is associated with
  greater disease severity than hepatitis B
  infection alone.
• Companies operating in this pipeline space
  include Cadila Healthcare and Chongqing Zhifei
  Biological Products.

4
The report also includes the following details-

• - Which companies are the most active within each
  pipeline?
• - Which pharmaceutical approaches are the most
  prominent at each stage of the pipeline and
  within each indication?
• - To what extent do universities and institutions
  play a role within this pipeline, compared to
  pharmaceutical companies?
• - What are the most important RD milestones and
  data publications to have happened in this
  disease area?
• - Understand the overall pipeline, with an
  at-a-glance overview of all products in
  therapeutic development for each indication
• - Assess the products in development in granular
  detail, with an up-to-date overview of each
  individual pipeline program in each indication
  and a comprehensive picture of recent updates and
  milestones for each
• - Analyze the companies, institutions and
  universities currently operating in the pipeline
  and the products being fielded by each of these
• - Understand the composition of the pipeline in
  terms of molecule type, molecular target,
  mechanism of action and route of administration

5

• To know more, click on the link below
• https//www.kenresearch.com/healthcare/pharmaceuti
  cals/hepatitis-drug-development/149726-91.html
• Related Report
• https//www.kenresearch.com/healthcare/pharmaceuti
  cals/hepatitis-drug-development/135641-91.html
• Contact Us
• Ken Research
• Ankur Gupta, Head Marketing Communications
• sales_at_kenresearch.com
• 91-9015378249

6
(No Transcript)